Abstract
Antisense oligonucleotide (ASO) biotechnology has been widely used to inhibit the expression of proteins involved in human disease. ASOs are designed to bind messenger RNA transcripts via Watson-Crick base-pairing and inhibit synthesis of targeted proteins. These proteins include protein kinases, growth factors, glutamate receptors, anti-apoptotic proteins, and proteins involved in genetic disorders. Non-mRNA targets such as the RNA component of the telomerase enzyme are also being explored. Pre-clinical and clinical trials using ASO biotechnology have progressed with standard ASOs such as phosphorothioates, but newer ASO analogs are rapidly being developed with the idea of enhancing specificity and biological activity. A current major research thrust is the design and testing of antisense oligonucleotides as anti-cancer drugs. The primary focus of this review is an analysis of recent uses of ASO biotechnology to inhibit anti-apoptotic gene expression in tumor cells.
Keywords: Anti-Apoptotic Proteins, Antisense Oligonucleotides, Neurodegenerative disorders, Crohns disease, Inflammatory Disorders, Hypertension, Beta-thalassemia, Cystic fibrosis, protein kinase A, testosterone-repressed prostate message, telomease, intrleukin
Current Drug Targets
Title: Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides
Volume: 2 Issue: 2
Author(s): Nicholas Delihas
Affiliation:
Keywords: Anti-Apoptotic Proteins, Antisense Oligonucleotides, Neurodegenerative disorders, Crohns disease, Inflammatory Disorders, Hypertension, Beta-thalassemia, Cystic fibrosis, protein kinase A, testosterone-repressed prostate message, telomease, intrleukin
Abstract: Antisense oligonucleotide (ASO) biotechnology has been widely used to inhibit the expression of proteins involved in human disease. ASOs are designed to bind messenger RNA transcripts via Watson-Crick base-pairing and inhibit synthesis of targeted proteins. These proteins include protein kinases, growth factors, glutamate receptors, anti-apoptotic proteins, and proteins involved in genetic disorders. Non-mRNA targets such as the RNA component of the telomerase enzyme are also being explored. Pre-clinical and clinical trials using ASO biotechnology have progressed with standard ASOs such as phosphorothioates, but newer ASO analogs are rapidly being developed with the idea of enhancing specificity and biological activity. A current major research thrust is the design and testing of antisense oligonucleotides as anti-cancer drugs. The primary focus of this review is an analysis of recent uses of ASO biotechnology to inhibit anti-apoptotic gene expression in tumor cells.
Export Options
About this article
Cite this article as:
Delihas Nicholas, Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides, Current Drug Targets 2001; 2 (2) . https://dx.doi.org/10.2174/1389450013348678
DOI https://dx.doi.org/10.2174/1389450013348678 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Protein Transduction Domains: Applications for Molecular Medicine
Current Gene Therapy Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Comparison Between 18F-Dopa and 18F-Fet PET/CT in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and Our Experience
Current Radiopharmaceuticals Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry Delineation of Current Development of Antimitotic Compounds Targeting Cytoskeletal Protein Tubulin and Microtubule in the Cancer Therapy
Current Chemical Biology The Role of Ghrelin Signals in Breast Cancer- A Systematic Review
Current Signal Transduction Therapy Computational Insights into the Role of Glutathione in Oxidative Stress
Current Neurovascular Research Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Thalidomide: An Overview of its Pharmacological Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pore-forming Peptides: A New Treatment Option for Cancer
Current Medicinal Chemistry Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Hsp90: A Novel Target for Cancer Therapy
Current Topics in Medicinal Chemistry Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review
Protein & Peptide Letters WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of β-Catenin during Oxidant Stress with Limited Effects upon Neuronal Autophagy
Current Neurovascular Research